Novartis Shs Sponsored American Deposit Receipt Repr 1 Sh $84.67

up +0.26


17/4/2014 06:40 PM  |  NYSE : NVS  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get NVS Trend Analysis - it has underperformed the S&P 500 by 2%

Partner Headlines

  1. Mallinckrodt, Questcor Merger Gets Mixed Reception

    IBD
  2. Trial Results Lift Drug Sector

    IBD
  3. Stock Futures Look Favorable; Legg Mason, Novartis, Climb

    IBD
  4. Market Wrap For March 27: Markets Lower Following Mixed Economic Data

    Benzinga
  5. Novartis drug lacks evidence

    IBD
  6. Market Wrap For March 25: Markets Snap Two-Day Losing Steak On Confidence ...

    Benzinga
  7. Google Honors Activist Dorothy Height & Her Contributions

    Benzinga
  8. Is Grifols Being Overlooked?

    GuruFocus
  9. Market Wrap For March 18: Markets Positive Despite Crimea Concerns

    Benzinga
  10. Hang Out on the Sidelines

    FoxBusiness
  11. Will Horizon Pharma Spike Again On Quarterly Report?

    IBD
  12. Pfizer Breast-Cancer Drug To Show If It's For Real

    IBD
  13. Teva upgraded on drug launch

    IBD
  14. Top Three Holdings of a Top Investment Advisory Firm

    GuruFocus
  15. Teva Upgraded On Strong Launch Of Next-Gen Copaxone

    IBD
  16. Arrowhead Surges As Analysts Laud Hepatitis B Drug

    IBD
  17. Novartis Vs. Everyone: Biologic Knockoffs

    YCharts
  18. European ETFs Flying Under The Radar

    Benzinga
  19. Market Wrap For February 19: Stocks Close Lower, Nasdaq Ends Winning Streak

    Benzinga
  20. Weekly 52-Week Highs Highlight: ORLY, LLL, BIIB, NVS

    GuruFocus
  21. Novartis' 'Cliffy' Business

    GuruFocus
  22. Market Wrap For January 29: Markets Lower on Fed Taper, Emerging Markets ...

    Benzinga
  23. Biogen MS Drug Tecfidera Outperforms; Outlook Light

    IBD
  24. Tug Of War In Ariad Pharmaceuticals

    Benzinga
  25. Benzinga's M&A Chatter for Monday January 27, 2014

    Benzinga
  26. NJ Woman Sues Novartis over Pricing of Similar Excedrin Pain Medicines

    Benzinga
  27. Wide Moat Stocks Against Two Value Systems

    YCharts
  28. Allergan

    IBD
  29. Cell Therapeutics to Reacquire Rights to Two Anti-Cancer Compounds from ...

    Benzinga
  30. No Imminent Widespread Outbreak of Human-to-Human Transmitted Avian Flu ...

    Benzinga
  31. EXCLUSIVE: No Imminent Widespread Outbreak of Human-to-Human Transmitted ...

    Benzinga
  32. Novartis faces criminal action

    IBD
  33. NOVARTIS

    IBD
  34. Correction Protection: Better Metric Finds Value

    YCharts
  35. Enanta Joins Big Leagues With Hepatitis C Drug

    IBD
  36. Jazz, Valeant Join Drug Makers' Q4 Merger Rush

    IBD
  37. Biologic Makers Thwart Generics: Winning Stocks

    YCharts
  38. Drugmaker Aptalis Files For IPO After Overhaul

    IBD
  39. Co-Pays: Skin In the Game If It Ain’t Your Skin?

    YCharts
  40. Novartis Offers Steady Profit, Dividend Growth

    IBD
  41. Apricus Expands Exclusive License Agreement With Sandoz Affiliate, Apricus ...

    Benzinga
  42. Top Guru-Bought European Stocks of the Third Quarter

    GuruFocus
  43. Retrophin Signs US License Agreement for Syntocinon Nasal Spray with Novartis ...

    Benzinga
  44. Biopharma Grifols Builds In Blood Therapies Worldwide

    IBD
  45. EU officials fine J&J, Novartis

    IBD
  46. Europe Cracks Down on Pharma Pay-to-Delay Deals

    YCharts
  47. Pfizer - Key Reasons to Long This Biopharmaceutical Giant

    GuruFocus
  48. US Stock Futures Rise; All Eyes On Jobs Report

    Benzinga
  49. Novartis Investigational Compound LBH589 Met Primary Endpoint in Phase ...

    Benzinga
  50. Pharma Stocks: R&D Spend and Returns

    YCharts
Trading Center